{
    "id": 11288,
    "cites": 30,
    "cited_by": 0,
    "reference": [
        "Adams G et al. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Consensus Statement on Antiretroviral Treatment for AIDS in Poor Countries.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d 2001. Available online: http://www.hsph.harvard.edu/bioethics/pdf/consensus_aids_therapy.pdf [accessed 30 May 2006] Alonso P et al. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Efficacy of the RTS, S/AS02A Vaccine Against Plasmodium Falciparum Infection and Disease in Young African Children: Randomised Controlled Trial.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Lancet 2004, 364(9443): 1411-1420.",
        "Angell M. The Truth About Drug Companies. Random House: New York, NY, 2004.",
        "Ballou W et al. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Update on the clinical development of candidate malaria vaccines.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d American Journal of Tropical Medicine and Hygiene 2004, 71(2 Supplement): 239-247.",
        "Barder O et al. Making Markets for Vaccines. Center for Global Development: Washington, DC, 2005. Available online: http://www.cgdev.org/section/initiatives/_active/vaccinedevelopment/ [accessed 30 May 2006] Berndt E, Hurvitz J. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Vaccine advance-purchase agreements for low-income countries: Practical issues.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health Affairs 2005, 24(3): 653-665.",
        "Berndt E et al. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Estimating the Required Volume of a Malaria Vaccine Commitment.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Mimeo: Cambridge, MA, 2003.",
        "Bohrer R, Prince J \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093A tale of two proteins: The FDA&apos;s uncertain interpretation of the Orphan Drug Act.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Harvard Journal of Law & Technology 1999, 12(2): 364-417.",
        "Brown G. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Speech by the RT Gordon Brown MP, Chancellor of the Exchequer at the BBC World Service Trust conference.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d 24 November, 2004. Available online: http://www.hmtreasury.",
        "gov.uk./newsroom_and_speeches/press/2004/press_94_04.cfm [accessed 30 May 2006] DiMasi J et al. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Price of Innovation: New Estimates of Drug Development Costs.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Health Economics 2003, 22: 151-185.",
        "Finkelstein A. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Static and Dynamic Effects of Health Policy: Evidence from the Vaccine Industry.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Quarterly Journal of Economics 2004, 119(2): 527-564.",
        "Global Alliance for Vaccines and Immunization (GAVI). \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Health, Immunization, and Economic Growth, Research Briefing #2, Vaccines are Cost-effective: A Summary of Recent Research.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d 2004. Available online: http://www.gavialliance.org/General_Information/Immunization_informa/Economic_Impact/vacc_ cost.php [accessed 30 May 2006] Grabowski H. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Increasing R&D Incentives for Neglected Diseases \u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c Lessons from the Orphan Drug Act.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Mimeo: Duke University, 2003.",
        "Grabowski H, Vernon J. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093A New Look at the Returns and Risks to Pharmaceutical R&D.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Management Science 1990, 36: 804-821.",
        "Grabowski H, Vernon J, DiMasi J. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Returns on Research and Development for 1990s New Drug Introductions.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d PharmacoEconomics 2002, 20 (Supplement 3): 11-29.",
        "HM Treasury. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Statement by G7 Finance Ministers and Central Bank Governors.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d2-3 December, 2005. Available online: http://www.hmtreasury.",
        "gov.uk/otherhmtsites/g7/news/g7_statement_031205.cfm [accessed 30 May 2006] Kremer M, Glennerster R. Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases. Princeton University Press: Princeton, NJ, 2004.",
        "McNeil D. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Plan to Bring Generic AIDS Drugs to Poor Nations.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d New York Times 2004, April 6: F06.",
        "Muraskin W. The War Against Hepatitis B: A History of the International Task Force on Hepatitis B Immunization. University of Pennsylvania Press: Philadelphia, PA, 1995.",
        "Neumann P et al. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Are Pharmaceuticals Cost-Effective? A Review of the Evidence.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Health Affairs 2000, 19(2): 92-109.",
        "Reuters. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Pfizer Announces Potential Malaria Discovery.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d June 17, 2003.",
        "Rin-Laures L-H, Janofsky D \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Recent developments concerning the Orphan Drug Act.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Harvard Journal of Law & Technology 1991, 4(Spring): 269-299.",
        "Robbins-Roth C. From Alchemy to IPO: The Business of Biotechnology. Perseus Publishing: Boulder, CO, 2000.",
        "Rosenthal M et al. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Promotion of Prescription Drugs to Consumers.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d New England Journal of Medicine 2002, 346(7): 498-505.",
        "Siegal J. Stocks for the Long Run. McGraw Hill: New York, NY, 1998.",
        "United States Bureau of the Census. International Data Base, Table 028: \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Age-Specific Fertility Rates and Selected Derived Measures.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d 2000. Available online: http://www.census.gov/ipc/www/idbnew.html [accessed 30 May 2006] World Bank. Disease Control Priorities in Developing Countries. Oxford Medical Publications, Oxford University Press for the World Bank: New York, NY, 1993.",
        "World Bank. World Development Indicators. World Bank: Washington, DC, 2005.",
        "World Health Organization (WHO). Investing in Health Research and Development: Report of the Ad Hoc Committee on Health Research Relating to Future Intervention Options. WHO: Geneva, 1996.",
        "World Health Organization (WHO). \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093World Malaria Situation in 1994, Part I.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Weekly Epidemiological Record 1997, 72(36): 269-274.",
        "World Health Organization (WHO). \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Less-Used Vaccines against Major Diseases Are CostEffective, Researchers Conclude.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Bulletin of the World Health Organization 2000, 78(2): 274.",
        "World Health Organization (WHO). World Health Report 2000. WHO: Geneva, 2000.",
        "World Health Organization (WHO). World Health Report 2001. WHO: Geneva, 2001.",
        "World Health Organization. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Vaccines, Immunizations, and Biologicals: Statistics and Graphs.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d 2002. Available online: http://www.who.int/vaccines-surveillance/StatsAndGraphs.htm [accessed 31 March 2006]"
    ]
}